Despite hurdles such as manufacturing
overcapacity, limited drug approvals and intense competition from Asian companies,
a new report from market research analysts Frost & Sullivan predicts revenues
in the North American fine chemicals sector will grow from $21.29bn (⁈17.78bn)
in 2005 to reach $28.62bn in 2011, driven by the production restructuring announced
by pharmaceutical majors.